表紙
市場調査レポート

転移性内分泌治療抵抗性(去勢抵抗性、アンドロゲン非依存性)前立腺癌:パイプライン分析

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline Review, H1 2016

発行 Global Markets Direct 商品コード 264086
出版日 ページ情報 英文 430 Pages
即納可能
価格
本日の銀行送金レート: 1USD=106.02円で換算しております。
Back to Top
転移性内分泌治療抵抗性(去勢抵抗性、アンドロゲン非依存性)前立腺癌:パイプライン分析 Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline Review, H1 2016
出版日: 2016年05月25日 ページ情報: 英文 430 Pages
概要

転移性内分泌治療抵抗性(去勢抵抗性、アンドロゲン非依存性)前立腺癌(mHRPC)とは、低テストステロン下でも前立腺特異抗原(SPA)が上昇する前立腺癌です。ホルモン療法に反応しなくなり、癌細胞周辺の組織や骨など他臓器への転移が起こります。mHRPCのもっとも重要な発症要因は加齢、環境ストレス、遺伝要因であり、症状は倦怠感、まひ、骨の痛み、下腰部痛または骨盤痛、体重の減少などが挙げられます。

当レポートでは、転移性内分泌治療抵抗性(去勢抵抗性、アンドロゲン非依存性)前立腺癌に対する治療薬の開発状況について調査分析し、パイプライン製品の概要、治験の段階別の製品の概要、主要企業プロファイル、薬剤のプロファイル、パイプライン製品の最新動向、最新ニュースとプレスリリースなどについて、体系的な情報を提供しています。

目次

イントロダクション

転移性内分泌治療抵抗性(去勢抵抗性、アンドロゲン非依存性)前立腺癌の概要

治療薬の開発

  • パイプライン製品:概要
  • パイプライン製品:比較分析

開発中の治療薬:企業別

調査中の治療薬:大学/研究機関別

パイプライン製品の概要

  • 後期段階の製品
  • 治験段階の製品
  • 初期段階の製品

開発中の製品:企業別

調査中の製品:大学/研究機関別

治療薬の開発に従事している企業

  • AB Science SA
  • AbbVie Inc.
  • Adamis Pharmaceuticals Corporation
  • Advaxis, Inc.
  • Ambrx, Inc.
  • Amgen Inc.
  • Armour Therapeutics Inc.
  • ArQule, Inc.
  • Arrowhead Pharmaceuticals, Inc.
  • AstraZeneca Plc
  • ATLAB Pharma SAS
  • Bavarian Nordic A/S
  • BIND Therapeutics, Inc.
  • Boehringer Ingelheim GmbH
  • Bristol-Myers Squibb Company
  • CellCentric Ltd
  • Corvus Pharmaceuticals, Inc.
  • CureVac GmbH
  • DexTech Medical AB
  • Eli Lilly and Company
  • Emergent BioSolutions Inc.
  • Endocyte, Inc.
  • ESSA Pharma Inc
  • F. Hoffmann-La Roche Ltd.
  • GenSpera, Inc.
  • Gilead Sciences, Inc.
  • Glactone Pharma AB
  • GlaxoSmithKline Plc
  • GTx, Inc.
  • Jiangsu Hengrui Medicine Co., Ltd.
  • Johnson & Johnson
  • Medivation, Inc.
  • Millennium Pharmaceuticals, Inc.
  • NewLink Genetics Corporation
  • Novartis AG
  • Oncogenex Pharmaceuticals, Inc.
  • Oncolytics Biotech Inc.
  • Orion Oyj
  • Pfizer Inc.
  • Progenics Pharmaceuticals, Inc
  • Sanofi
  • Sotio a.s.
  • Supratek Pharma Inc.
  • 大鵬薬品工業
  • 武田薬品工業
  • Tesaro, Inc.
  • Tiltan Pharma Ltd.
  • Tokai Pharmaceuticals, Inc.
  • TRACON Pharmaceuticals, Inc.
  • UbiVac, LLC
  • Viralytics Ltd.

治療薬の評価

  • 単独療法の製品
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤のプロファイル

パイプライン製品の最新動向

休止中のプロジェクト

開発が中止された製品

製品開発のマイルストーン

  • 最新ニュースとプレスリリース

付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC8003IDB

Summary

Global Markets Direct's, 'Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline Review, H1 2016', provides an overview of the Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer
  • The report reviews pipeline therapeutics for Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer therapeutics and enlists all their major and minor projects
  • The report assesses Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
  • Introduction
  • Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Overview
  • Therapeutics Development
  • Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Therapeutics under Development by Companies
  • Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Therapeutics under Investigation by Universities/Institutes
  • Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline Products Glance
  • Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Products under Development by Companies
  • Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Products under Investigation by Universities/Institutes
  • Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Companies Involved in Therapeutics Development
  • Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Therapeutics Assessment
  • Drug Profiles
  • Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Recent Pipeline Updates
  • Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Dormant Projects
  • Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Discontinued Products
  • Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Product Development Milestones
  • Appendix

List of Tables

  • Number of Products under Development for Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, H1 2016
  • Number of Products under Development for Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Number of Products under Development by Companies, H1 2016 (Contd..1)
  • Number of Products under Development by Companies, H1 2016 (Contd..2)
  • Number of Products under Development by Companies, H1 2016 (Contd..3)
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Development, H1 2016
  • Products under Development by Companies, H1 2016
  • Products under Development by Companies, H1 2016 (Contd..1)
  • Products under Development by Companies, H1 2016 (Contd..2)
  • Products under Development by Companies, H1 2016 (Contd..3)
  • Products under Development by Companies, H1 2016 (Contd..4)
  • Products under Investigation by Universities/Institutes, H1 2016
  • Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by AB Science SA, H1 2016
  • Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by AbbVie Inc., H1 2016
  • Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Adamis Pharmaceuticals Corporation, H1 2016
  • Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Advaxis, Inc., H1 2016
  • Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Ambrx, Inc., H1 2016
  • Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Amgen Inc., H1 2016
  • Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Armour Therapeutics Inc., H1 2016
  • Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by ArQule, Inc., H1 2016
  • Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Arrowhead Pharmaceuticals, Inc., H1 2016
  • Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by AstraZeneca Plc, H1 2016
  • Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by ATLAB Pharma SAS, H1 2016
  • Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Bavarian Nordic A/S, H1 2016
  • Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by BIND Therapeutics, Inc., H1 2016
  • Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Boehringer Ingelheim GmbH, H1 2016
  • Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Bristol-Myers Squibb Company, H1 2016
  • Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by CellCentric Ltd, H1 2016
  • Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Corvus Pharmaceuticals, Inc., H1 2016
  • Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by CureVac GmbH, H1 2016
  • Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by DexTech Medical AB, H1 2016
  • Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Eli Lilly and Company, H1 2016
  • Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Emergent BioSolutions Inc., H1 2016
  • Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Endocyte, Inc., H1 2016
  • Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by ESSA Pharma Inc, H1 2016
  • Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by F. Hoffmann-La Roche Ltd., H1 2016
  • Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by GenSpera, Inc., H1 2016
  • Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Gilead Sciences, Inc., H1 2016
  • Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Glactone Pharma AB, H1 2016
  • Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by GlaxoSmithKline Plc, H1 2016
  • Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by GTx, Inc., H1 2016
  • Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Jiangsu Hengrui Medicine Co., Ltd., H1 2016
  • Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Johnson & Johnson, H1 2016
  • Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Medivation, Inc., H1 2016
  • Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Millennium Pharmaceuticals, Inc., H1 2016
  • Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by NewLink Genetics Corporation, H1 2016
  • Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Novartis AG, H1 2016
  • Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Oncogenex Pharmaceuticals, Inc., H1 2016
  • Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Oncolytics Biotech Inc., H1 2016
  • Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Orion Oyj, H1 2016
  • Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Pfizer Inc., H1 2016
  • Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Progenics Pharmaceuticals, Inc., H1 2016
  • Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Sanofi, H1 2016
  • Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Sotio a.s., H1 2016
  • Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Supratek Pharma Inc., H1 2016
  • Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Taiho Pharmaceutical Co., Ltd., H1 2016
  • Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Takeda Pharmaceutical Company Limited, H1 2016
  • Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Tesaro, Inc., H1 2016
  • Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Tiltan Pharma Ltd., H1 2016
  • Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Tokai Pharmaceuticals, Inc., H1 2016
  • Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by TRACON Pharmaceuticals, Inc., H1 2016
  • Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by UbiVac, LLC, H1 2016
  • Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Viralytics Ltd., H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Number of Products by Stage and Target, H1 2016
  • Number of Products by Stage and Mechanism of Action, H1 2016
  • Number of Products by Stage and Route of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
  • Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics - Recent Pipeline Updates, H1 2016
  • Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Dormant Projects, H1 2016
  • Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Dormant Projects (Contd..1), H1 2016
  • Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Dormant Projects (Contd..2), H1 2016
  • Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Dormant Projects (Contd..3), H1 2016
  • Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Discontinued Products, H1 2016
  • Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Discontinued Products (Contd..1), H1 2016

List of Figures

  • Number of Products under Development for Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, H1 2016
  • Number of Products under Development for Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Number of Products by Top 10 Targets, H1 2016
  • Number of Products by Stage and Top 10 Targets, H1 2016
  • Number of Products by Top 10 Mechanism of Actions, H1 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016
  • Number of Products by Top 10 Routes of Administration, H1 2016
  • Number of Products by Stage and Top 10 Routes of Administration, H1 2016
  • Number of Products by Top 10 Molecule Types, H1 2016
  • Number of Products by Stage and Top 10 Molecule Types, H1 2016
Back to Top